These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37996934)

  • 21. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
    Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
    Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.
    Yücel BB; Aydog O; Nalcacioglu H; Yılmaz A
    Front Pediatr; 2021; 9():710501. PubMed ID: 34568239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
    Ozkan S; Atas B
    J Pak Med Assoc; 2017 Jun; 67(6):945-947. PubMed ID: 28585601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.
    Sener S; Cam V; Batu ED; Kasap Cuceoglu M; Balik Z; Aliyev E; Bayindir Y; Basaran O; Bilginer Y; Ozen S
    Rheumatology (Oxford); 2023 Nov; 62(11):3700-3705. PubMed ID: 36961326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab.
    Druyan A; Giat E; Livneh A; Grossman C; Ben-Zvi I; Lidar M
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):75-79. PubMed ID: 34369359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States.
    Hur P; Lomax KG; Ionescu-Ittu R; Manceur AM; Xie J; Cammarota J; Gautam R; Sanghera N; Kim N; Grom AA
    Pediatr Rheumatol Online J; 2021 Sep; 19(1):143. PubMed ID: 34521444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
    Yildirim T; Yilmaz R; Uzerk Kibar M; Erdem Y
    J Nephrol; 2018 Jun; 31(3):453-455. PubMed ID: 29446001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
    Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2015 Mar; (3):CD010893. PubMed ID: 25791871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canakinumab eliminates resistant familial Mediterranean fever in a Japanese girl.
    Yasuda R; Mizuochi T; Kitamura M; Migita K; Yamashita Y
    Pediatr Int; 2019 Nov; 61(11):1173-1174. PubMed ID: 31724243
    [No Abstract]   [Full Text] [Related]  

  • 32. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M
    Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
    Atas N; Eroglu GA; Sodan HN; Ozturk BO; Babaoglu H; Satis H; Karadeniz H; Guler AA; Salman RB; Goker B; Ozturk MA; Haznedaroglu S; Tufan A
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):30-36. PubMed ID: 34251317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
    Front Immunol; 2020; 11():971. PubMed ID: 32670263
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
    Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment.
    Alpa M; Roccatello D
    Drug Des Devel Ther; 2015; 9():1983-7. PubMed ID: 25945034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canakinumab for the treatment of familial Mediterranean fever.
    Ozdogan H; Ugurlu S
    Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab.
    Koné-Paut I; Piram M; Benseler S; Kuemmerle-Deschner JB; Jansson A; Rosner I; Tommasini A; Murias S; Karadag O; Levy J; McCreddin S; Migliaccio M; De Benedetti F
    Joint Bone Spine; 2022 Nov; 89(6):105448. PubMed ID: 35944600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'.
    Satış H; Aydemir E; İzmirlioğlu K; Tufan A
    Ann Rheum Dis; 2022 Dec; 81(12):e256. PubMed ID: 32988847
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.
    Aydin EA; Baglan E; Kocamaz NG; Bagrul İ; Tuncez S; Ozdel S
    Clin Rheumatol; 2024 Jan; 43(1):387-392. PubMed ID: 37658934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.